The study is being done to learn how well tirabrutinib (investigational drug) works against cancer as compared to the combination of rituximab and temozolomide (comparator) in participants with PCNSL. We will also learn more about the safety of tirabrutinib and look at how tirabrutinib may affect the body.

To be in this study: o You must have confirmed PCNSL that has come back after treatment (relapsed) or has not improved with prior treatment (refractory) o You must have received methotrexate previously. You will be required to only take the assigned study drug to treat your cancer while on this study. If you believe that you will want to receive other therapy for your cancer, you should not participate in this study. You must agree to not participate in any other study while participating in this study or take any other therapy for your cancer while participating in this study.

This trial will be comparing a new drug against investigator's choice of therapy in the treatment of endometrial cancer that is HER 2 in addition to using a new assay to measure Her2

After the determination is made that it is safe for the patient to participate, the consent form will be signed, and the patient will have scans and blood work taken. The subject is expected to come to all study visits, report to the study team how they feel and let them know about any changes in medication. The study treatments will be given once a week for 21 or 28 days until the medication no longer works, you no longer want to take the medications, or the study doctor feels it is not safe for you to continue. After you complete treatment, you will be seen by the study team monthly for three months then followed for survival for 5 years.

$125 for every completed visit.

The GAME-ONc Study aims to explore how video games can support teens and young adults going through cancer treatment. We will talk with adolescents and young adults with cancer, their parents, and healthcare providers to better understand what emotional, social, and practical challenges young people face during treatment, and how a video game intervention might help. The study will also ask participants what kinds of game features they’d like to see, such as whether the game should be single-player or involve someone else, what topics it should include (like coping strategies, health behaviors, or ways to connect with others), and how to make it easy and enjoyable to use. Ultimately, the feedback from this project will guide the design of a video game prototype tailored for teenagers and young adults with cancer, setting the stage for future testing and development.

Participants will complete a brief demographic and gameplay preferences questionnaire and then take part in a one-time focus group session (approximately 1-1.5 hours) conducted via Microsoft Teams or in person. During the focus group, participants will discuss psychosocial needs of adolescents and young adults with cancer and share their opinions on desired features, content, and usability of a proposed video game intervention. The session will be audio and video recorded for research purposes.

100

The overall goal of this study is to determine the effects, good and/or bad, of a new treatment regimen that combines dasatinib or imatinib to chemotherapy with blinatumomab in patients with Ph+ and ABL-class Ph-like B-ALL. In this study, you will receive blinatumomab with chemotherapy and dasatinib or imatinib.

The overall goal of this study is to determine the effects, good and/or bad, of a new treatment regimen that combines dasatinib or imatinib to chemotherapy with blinatumomab in patients with Ph+ and ABL-class Ph-like B-ALL. In this study, you will receive blinatumomab with chemotherapy and dasatinib or imatinib. All patients on this study will receive the immunotherapy medicine blinatumomab in addition to chemotherapy plus dasatinib or imatinib. The treatment on this study takes about 2 years. It is divided into 7-8 phases of therapy. Participants will be asked to do some optional tests that will help to learn more about their immune system. To do these tests, we would like to take about 2 teaspoons (6-10 ml) of peripheral blood and about 1 teaspoon (3-5 ml) of bone marrow (at the time of standard procedures) at different time points. These tests will not require additional needle sticks or additional procedures. There will also be optional collection of bone marrow and/or blood for banking for future research.

The purpose of this study is to find out if gene expression signatures are different in people with cancer associated dermatomyositis (CAM) and CAM negative (CAM-) patients. Dermatomyositis (DM) participants will provide up to 3 blood samples and 2 skin samples for testing, including testing that has to do with genes. Control participants (those who do not have a skin condition) will provide up to 2 skin samples for testing, including testing that has to do with genes.

Only control subjects are being recruited through StudyFinder. There will be one in-person visit where up to 2 skin samples will be collected using a punch biopsy.

$50.00 per skin sample

Ewing sarcoma (EWS) and osteosarcoma primarily affect adolescents and young adults. Common treatments include chemotherapy, surgery and radiation, however, there have been few recent advancements in the standard of care. By incorporating eflornithine (DFMO) as an additional therapy and/or maintenance therapy we hope to safely observe improved event-free survival and overall survival. There are 5 cohorts covered under this master protocol.

Patients will come in for screening and at the start of the study, and then approximately once a month during chemotherapy (if applicable). Patients may need to be seen more often for standard of care. During the DFMO alone phase, patients will come in once a month for the first 3 months, and then once every 3 months until the end of study treatment. During these visits patients will have tests done which may include a physical exam, blood tests, cardiac tests, hearing tests, or tumor evaluations.

The purpose of this Expanded Access Program is to determine the safety of cretostimogene in patients with BCG -unresponsive high-risk Non Muscle Invasive Bladder Cancer and to determine the Complete Response rate at any time of cretostimogene in patients with BCG-unresponsive CIS with or without HG Ta/T1 papillary NMIBC

Eligible participants will receive the study drug, Cretostimogene every week for 6 treatments, followed by a maintenance period as directed by the Investigator. There are 3 phases in the study: Screening Phase, Treatment Phase, and Follow-Up Phase. The Screening Phase will last up to 16 weeks (4 months). The Treatment Phase can continue for up to 2 years from the start of study treatment unless your cancer gets worse or recurs. The Follow-Up Phase will include one visit every 3 months after the last study treatment. If your cancer has not come back but you stop treatment before the end of the Treatment Phase, you will also have a study visit every 3 months in the Follow-Up Phase to confirm whether your cancer gets worse or recurs, until 2 years after the start of treatment. If your cancer has gotten worse or recurs at any point during the study, you will not be scheduled to return to the clinic/hospital for the study after the final visit, but you will be contacted approximately every 6 months.

Physical activity is the cornerstone of overall health and well-being and is associated with better survival and survivorship outcomes in pediatric cancer patients. This research is being conducted to identify biomarkers associated with the physical activity status of 90 children diagnosed with leukemia undergoing therapy.

During the first visit, you will answer demographic questions and provide medical history. You will then be asking to wear a Fitbit for at least 7 consecutive days, and participating in a second visit to collect saliva and blood samples

This trial will examine if the dose of drug determined in the Phase `1 portion can stop the cancer from growing.

There will be a screening period after you sign consent. You will have labs drawn and scans done to make sure it is safe for you to participate in this study. During the first 2 cycles, you will need to come to the clinic a total of 6 times. We do this to make sure you are feeling ok while taking these study medications. From C3 onward you will only need to come into the clinic twice. You will need to keep all of your clinic appointments, tell the study doctor how you are feeling and make sure that you tell them about any and all medications you are taking.

This a pilot study that will evaluate how feasible it is to use a questionnaire on paper, tablet or QR code to assess what barrier patient face to enroll in clinical trials at PSCI

Patient will fill out a 5 minute survey either on paper, tablet or on their own device.

The purpose of this clinical trial is to check the effect RBS2418 in combination with tremelimumab and durvalumab (referred to as STRIDE) may have on cancer and to determine which of the two RBS2418 doses is better and will be selected for further investigation.

Participation may last up to approximately 27-30 months and require several visits depending on how you do on the study, with each visit expected to take 2-4 hours unless you agree to participate in the subgroup that requires more blood collection. Blood will be drawn at each visit. Participants may also have to provide urine samples. A tumor specimen will be required at the screening visit. Optional specimens may be taken over the course of the study, if agreed upon. Every 6-8 weeks, a tumor scan will be completed. If the participant is assigned to Arm A or B, they will take the study drug daily, and all participants will have one infusion of tremelimumab and monthly infusions of durvalumab.